These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30048166)

  • 1. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
    Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
    Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
    Pelewicz K; Miśkiewicz P
    J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
    Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
    Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
    Park J; Kim J; Kim SS; Choi HY
    Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
    Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
    Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
    Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
    Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
    Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy.
    Walasik-Szemplińska D; Kamiński G; Sudoł-Szopińska I
    Thyroid Res; 2019; 12():13. PubMed ID: 31890036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
    Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
    J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
    Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
    Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
    Kemchoknatee P; Tangon D; Srisombut T
    BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
    Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
    Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
    Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
    Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
    [No Abstract]   [Full Text] [Related]  

  • 16. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
    Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome.
    Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
    Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
    Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.